Bispecific Antibody Development Service
In recent years, there has been a growing interest in the field of pharmaceutical and academic research regarding bispecific antibodies (BsAb). Alfa Cytology offers a tailored bladder cancer bispecific antibody development service to meet the specific requirements of our clients.
Bispecific Antibody Therapy for Bladder Cancer
Bispecific antibodies are artificially engineered antibodies that possess two specific antigen-binding sites. They serve as a bridge between target cells and functional molecules or cells, thereby stimulating a targeted immune response. Due to their unique structure, remarkable clinical effects, and particularly their therapeutic efficacy in tumor treatment, these antibodies have become a focal point in the field of antibody engineering. They hold immense potential for immunotherapy in bladder cancer.
Fig.1 Overview of bispecific antibody-based drugs for the treatment of bladder cancer. (Bogen, J. P., et al. 2021)
A number of bispecific antibodies are being developed today for the therapy of bladder cancer.
| Drug (Target) |
Disease |
Phase |
Status |
| Orlotamab (CD3xB7-H3) |
Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-Small Cell Lung Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Thyroid Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Colon Cancer, Soft Tissue Sarcoma |
I |
Terminated (Business decision (not for safety reasons)) |
| Advanced Solid Tumors |
I |
Active, not recruiting |
| ATOR-1015 (CTLA-4 × OX40) |
Solid Tumor Neoplasms |
I |
Recruiting |
| PRS-343 (HER2 × 4-1BB) |
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor |
I |
Suspended (Partial clinical hold) |
| HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor |
I |
Suspended (Partial clinical hold) |
Our Services
The bispecific antibodies are artificially engineered molecules that facilitate the simultaneous identification of two or more distinct antigens. Alfa Cytology takes pride in introducing our comprehensive and tailored services for the development of bispecific antibodies.
Project Study
We begin by thoroughly understanding your project requirements and objectives. Our team of experts collaborates closely with you to define the scope, timelines, and desired outcomes of the bispecific antibody development project for bladder cancer treatment.
Bispecific Antibody Format Definition
Next, we meticulously analyze the target antigens and signaling pathways involved in bladder cancer progression. Based on this assessment, we work with you to define the optimal bispecific antibody format tailored to your specific therapeutic goals and experimental needs.
Bispecific Antibody Design
Our experienced team utilizes state-of-the-art computational modeling and design tools to engineer bispecific antibodies with precise dual-targeting capabilities. Through rational design strategies, we ensure the efficient binding of the antibody to target antigens associated with bladder cancer.
Gene Synthesis
Once the bispecific antibody design is finalized, we proceed with gene synthesis to generate the DNA sequences encoding the antibody constructs. Our gene synthesis process employs advanced molecular biology techniques to ensure accurate assembly and verification of the bispecific antibody genes.
Antibody Production
With the synthesized genes in hand, we initiate the production of bispecific antibodies using cutting-edge expression systems. Our state-of-the-art facilities and optimized production protocols ensure the efficient expression and purification of high-quality bispecific antibodies.
Potency Assessment
To assess the potency and efficacy of the produced bispecific antibodies, we perform comprehensive in vitro and in vivo studies, providing critical insights into the therapeutic potential of the developed antibodies for bladder cancer treatment.
Contact Us
Alfa Cytology boasts extensive expertise in delivering cutting-edge and sophisticated bispecific antibody development services tailored precisely to meet the unique requirements of our esteemed clientele. Please feel free to contact us via email or phone without any hesitation, so that we can cater to your specific needs.
Reference
- Bogen, J. P., Grzeschik, J., and et al. Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics. Frontiers in oncology, 2021, 11, 672262.
For research use only. Not intended for any clinical use.
Related Services
